Last spring, as Aerie Pharmaceuticals execs rushed to man the ramparts as its share price tanked following the failure of its glaucoma drug Rhopressa, the company insisted that a slight change to its late-stage program would have been enough to get them over the goal line. So this morning, in a head-snapping turnaround, shares jumped 50% as the FDA proved amenable to making some changes that might let another Phase III trial succeed.

…read more

Source: Aerie Pharma shares soar as FDA lowers the hurdle for PhIII


0 No comments